A Phase III, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab IMAB362 Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin CLDN18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction GEJ Adenocarcinoma

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT03653507

Study #:
STUDY00143607

Start Date:
Jan 01, 0001

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03653507

View Complete Trial Details & Eligibility at ClinicalTrials.gov